This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignees: Actgen Inc, Medical Biological Laboratories Co., Ltd., Microbial Chemistry Research Foundation. Active years: 2014-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1 
1 out of 43 
1 out of 44 Years Active: 2014-2016
Title: Masunori Kajikawa: Innovator in Cancer Treatment
Introduction
Masunori Kajikawa is a notable inventor based in Komagane, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and development of monoclonal antibodies. With a total of 2 patents, his work focuses on identifying target molecules that can effectively combat various types of cancer.
Latest Patents
Kajikawa's latest patents include the development of an Anti-CXADR antibody. The objective of this invention is to find a target molecule that is effective for cancer treatments and to provide an antibody capable of specifically binding to this molecule. The research revealed that CXADR is involved in tumor formation. A monoclonal antibody against CXADR was prepared, demonstrating anti-cancer activity against prostate, pancreatic, and colorectal cancer cells. Additionally, the antibody exhibited both ADCC and CDC activities, showcasing its potential as a therapeutic agent. Another significant patent involves an antibody with anti-cancer activity, which was developed using the SST-REX method. This invention led to the identification of a monoclonal antibody that binds to the PODXL2 protein, exhibiting excellent anti-cancer activities.
Career Highlights
Throughout his career, Kajikawa has worked with various organizations, including Actgen Inc and the Microbial Chemistry Research Foundation. His research has contributed to advancements in cancer therapies, particularly through the development of monoclonal antibodies that target specific proteins associated with cancer cells.
Collaborations
Kajikawa has collaborated with notable colleagues such as Masahito Sugiura and Kazuyuki Atarashi. These partnerships have enhanced his research efforts and contributed to the success of his innovative projects.
Conclusion
Masunori Kajikawa's work in the field of cancer treatment exemplifies the impact of innovation in medical research. His patents and collaborations highlight his commitment to developing effective therapies for cancer patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile